Marina Simão Bertani

Marina Simão Bertani

Auto-generated profile, based on publicly available information

Marina Simão Bertani

Department of Medicine Universidade de Caxias do Sul Caxias do Sul RS Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
Verified
Journal Article
Closed access
GRGiuseppe Roselli
Giuseppe Roselli
MAM. Abbrescia
M. Abbrescia
GIG. Iaselli
G. Iaselli
BMB. Marangelli
B. Marangelli
SNS. Natali
S. Natali
WWWilliam Whitaker
William Whitaker

1 August 2013 in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
Verified
Journal Article
Open access
MAM. Anelli
M. Anelli
RFR. Baldini Ferroli
R. Baldini Ferroli
MBM. Bertani
M. Bertani
ACA. Calcaterra
A. Calcaterra
Fabrizio CoccettiFabrizio Coccetti
Fabrizio Coccetti
AZA. Zallo
A. Zallo

1 October 2009
Verified
Conference Paper
Closed access
PDF file
SPS. Piano
S. Piano
NGN. Grion
N. Grion
EBE. Bonifazi
E. Bonifazi
MBM. Bregant
M. Bregant
PCP. Camerini
P. Camerini
FCFor the FINUDA Collaboration
For the FINUDA Collaboration

18 November 2025 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
HPHenrique Provinciatto
Henrique Provinciatto
MBMaria Esther Barbalho
Maria Esther Barbalho
PCPedro Matos da Câmara
Pedro Matos da Câmara
MBMarina Simão Bertani
Marina Simão Bertani
AMAlice Deberaldini Marinho
Alice Deberaldini Marinho
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
Objective: Thyroid peroxidase antibody (TPOAb) is a prevalent condition amongst women of reproductive age and has been associated with adverse pregnancy outcomes. However, there is currently no proven treatment for euthyroid pregnant women with TPOAb. Therefore, we aimed to investigate the efficacy of levothyroxine treatment in this population. Methods: We searched PubMed, Embase and Cochrane Central from inception to or randomized controlled trials (RCTs) comparing levothyroxine with placebo or no treatment in euthyroid pregnant women who were positive for TPOAb. Our main outcomes were miscarriage, preterm birth, and live birth. We performed subgroup analysis based on recurrent pregnancy loss (RPL). Results: We included 8 RCTs comprising 1,645 pregnant women, of whom 814 (49.5%) were randomized to receive levothyroxine. Pregnant women treated with levothyroxine had significantly lower miscarriages (RR 0.78; 95% CI 0.63-0.98; p=0.035). No significant difference was found regarding pre-term birth (RR 0.78; 95% CI 0.55-1.13; p=0.189) and live birth (RR 1.05; 95% CI 0.99-1.12; p=0.097). Our subgroup analysis demonstrated a significant interaction (p=0.048) between patients with RPL (RR 1.21; 95% CI 1.03-1.42; p=0.023) and no RPL (RR 1.00; 95% CI 0.92-1.09; p=0.922). Conclusion: Levothyroxine reduced miscarriage in pregnant women with TPOAb and improved live birth rate when associated with RPL. Our subgroup analysis also provides evidence that levothyroxine may have a higher benefit for patients with a history of RPL.